KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Xenon Pharmaceuticals' Other Non-Current Liabilities changed N/A to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $70000.0 for FY2016, which is 4736.84% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Other Non-Current Liabilities of $3.2 million as of Q3 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Other Non-Current Liabilities peaked at $3.2 million during Q3 2025, and registered a low of $3.2 million during Q3 2025.